Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of HMPL-760 in Previously Treated CLL/SLL or NHL
NCT05176691Phase 1Withdrawn
- Sponsor
- HUTCHMED
- Start
- Feb 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of HMPL-760 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin lymphoma (NHL) and 7 more, sponsored by HUTCHMED. Primary endpoints: Incidence of Dose-Limiting Toxicities up to 28 days, Incidence of Adverse Events and Serious Adverse Events and 2 more. Planned start Feb 2022; status: withdrawn.
02
Drugs
HMPL-760
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT05176691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176691.